Adjuvant treatment with cemiplimab-rwlc (Libtayo) was associated with a similar incidence of second primary tumors (SPTs) compared with placebo in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and…
Rate of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC
